Who are Drug: YAZ flex (SH T00186D)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FEMCON® Fe, Ortho Tri-Cyclen LO, Ortho Tri Cyclen, Kariva®, DRSP-EE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drug-yaz-flex-sh-t00186d.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Drug: YAZ flex (SH T00186D) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug: YAZ flex (SH T00186D) (Drug: YAZ flex (SH T00186D)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive (combined hormonal contraceptive). Area: Contraception / Women's Health.

phase 3 Oral contraceptive (combined hormonal contraceptive) Estrogen and progesterone receptors Contraception / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Drug: YAZ flex (SH T00186D) (Drug: YAZ flex (SH T00186D)) — Bayer. YAZ flex is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol and drospirenone, with a flexible dosing regimen.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Drug: YAZ flex (SH T00186D) TARGET	Drug: YAZ flex (SH T00186D)	Bayer	phase 3	Oral contraceptive (combined hormonal contraceptive)	Estrogen and progesterone receptors
FEMCON® Fe	FEMCON® Fe	Teva Pharmaceuticals USA	marketed	Oral contraceptive (combined estrogen-progestin)	Estrogen and progesterone receptors; LH/FSH suppression
Ortho Tri-Cyclen LO	Ortho Tri-Cyclen LO	Bristol-Myers Squibb	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Ortho Tri Cyclen	Ortho Tri Cyclen	Virginia Commonwealth University	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Kariva®	Kariva®	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
DRSP-EE	DRSP-EE	Organon and Co	phase 3	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive (combined hormonal contraceptive) class)

Bayer · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Organon and Co · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
Virginia Commonwealth University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drug: YAZ flex (SH T00186D) — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-yaz-flex-sh-t00186d. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab